加科思(01167.HK)自主研發抑制劑獲批三期臨床研究

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

加科思(01167.HK)自主研發抑制劑獲批三期臨床研究

阿思達克 02-18 20:37

加科思－Ｂ(01167.HK)公布，公司自主研發的SHP2抑制劑JAB-3312與KRAS G12C抑制劑戈來雷塞聯合用藥獲國家藥品監督管理局藥品審評中心批准註冊性三期臨床試驗。此次臨床試驗旨在評估JAB-3312與戈來雷塞聯合用於KRAS G12C突變的一線非小細胞肺癌患者的療效及安全性，試驗的對照組是目前一線非小細胞肺癌的標準療法。

加科思-B(01167.HK)

Relevant Stocks

加科思-B(01167.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

加科思(01167.HK)自主研發抑制劑獲批三期臨床研究

Services

About Us

Agreement Statement